

SEPPO  LAINE PATENT AND TRADEMARK AGENTS
EUROPEAN PATENT ATTORNEYS
P A T E N T T I T O I M I S T O REG. No. 342.419 VAT No. FI 05905255

SEPPO E. LAINE *
CHRISTOFFER SUNDMAN *
JARI LIPSANEN *
SIMO HOVI *
SISKO KNUTH-LEHTOLA *
JARKKO TILIKAINEN *
TOM-ERIK HAGELBERG
PIA KOSTIAINEN
SAKARI ARVELA
KATHY WASSTRÖM
SOLVEIG STRÖMSHOLM

FLEUCHAUS & GALLO
Dr. Bojan Savic
Melchiorstr. 42
D81479 München
Germany

Fleuchaus & Gallo
Patent- und Rechtsanwälte

16. Nov. 2007

Frist:

WV:

16 November 2007

VIITTEENNE:
YOUR REFERENCE:

P1107FIEPPC

BY TELEFAX AND AIR MAIL

VIITTEEMME:
OUR REFERENCE:

KELLE1FI
P6191FIEP

Attention: Dr Bojan Savic

Dear Dr Savic,

Re: Finnish part of EP Patent No. 1 410 014, Ruprecht Keller

Thank you for your email of 24 October 2007, regarding the need for obtaining an authorization to use PEG 300 and 600 in drug testing in a method according to the above-identified patent.

With reference to our telephone discussion on 13 November 2007, we can confirm the following:

We have contacted the National Agency for Medicines and discussed the matter with the head of the clinical department, Dr Esko Nuotto.

Based on that discussion we conclude that the National Agency for Medicines is not the competent authority for dealing with the matter. The reason is that competence of the National Agency for Medicines is limited to medicines and diagnostic agents and their use. The testing of healthy human individuals, e.g. prisoners and athletics, for determining potential use of drugs cannot be considered a medical use or a diagnostic use.

Dr Nuotto suggested that, in principle, the proper authority for considering the use of PEG 300 or 600 might be the National Agency for Chemicals. However, in view of the fact that both chemicals are well-known and their pharmacological safety has already been checked, there is, in our opinion, no reason to contact the chemicals authority.

Thus, in conclusion: in our opinion, the use of PEG 300 or 600 in the method described in EP Patent No. 1 410 014 does not require any authorization from the medical authorities in Finland. We do not even see any reason for filing a request for written confirmation by the National Agency for Medicines.

SEPPO LAINE OY

PL 339 P.O.B. 339
00181 HELSINKI, FINLAND

TOIMISTO OFFICE
ITÄMERENKATU 3 B
00180 HELSINKI, FINLAND

* SUOMEN PATENTTIASIAMIESYHDISTYS
RY:N JÄSEN

* MEMBER OF FICPI
* MEMBER OF EPI
* OHIM REPRESENTATIVE



PUHELIN PHONE

NAT. 09-68 59 560
INT. + 358 - 9 -68 59 560
FAX + 358 - 9 -68 595610

SÄHKÖPOSTI E-MAIL
seppo.laine@seppolaine.fi

PANKIT BANKERS


NORDEA 215318 - 80138
SWIFT (BIC): NDEAFIHH
IBAN: FI 62 2153 1800 0601 38

SAMPO 800018 - 1108518
SWIFT (BIC): PSPBFIHH
IBAN: FI 80 5000 1801 1085 16

Although we hope the above information is useful to you, we should be happy to answer any additional questions that you may have.

Our debit note is enclosed.

Yours sincerely,
SEPPO LAINE OY



Christoffer Sundman

Enc. debit note

/chs/mn/